Profound Medical to Participate in the Stifel 2024 Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company specializing in customizable, incision-free therapies, will present an update at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:45 a.m. Eastern Time in NYC.
The presentation will be available live and archived on the Company's website under the 'Webcasts' section in the Investors area.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), un'azienda di dispositivi medici in fase commerciale specializzata in terapie personalizzabili e senza incisioni, presenterà un aggiornamento alla Stifel 2024 Healthcare Conference il martedì 19 novembre 2024, alle 9:45 a.m. Eastern Time a New York.
La presentazione sarà disponibile in diretta e archiviata sul sito web dell'azienda nella sezione 'Webcasts' nell'area Investitori.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), una empresa de dispositivos médicos en etapa comercial especializada en terapias personalizables y sin incisiones, presentará una actualización en la Stifel 2024 Healthcare Conference el martes 19 de noviembre de 2024, a las 9:45 a.m. hora del Este en Nueva York.
La presentación estará disponible en vivo y archivada en el sitio web de la compañía en la sección 'Webcasts' del área de Inversores.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), 개인 맞춤형 무절개 치료에 전문화된 상업 단계의 의료 기기 회사는 Stifel 2024 Healthcare Conference에서 2024년 11월 19일 화요일 오전 9:45 (동부 표준시)에 뉴욕에서 업데이트를 발표할 예정입니다.
발표는 회사 웹사이트의 'Webcasts' 섹션의 투자자 영역에서 실시간 및 아카이브로 제공됩니다.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), une entreprise de dispositifs médicaux en phase commerciale spécialisée dans les thérapies personnalisables sans incision, présentera une mise à jour lors de la Stifel 2024 Healthcare Conference le mardi 19 novembre 2024 à 9h45, heure de l'Est à New York.
La présentation sera disponible en direct et archivée sur le site de la société dans la section 'Webcasts' de l'espace Investisseurs.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN), ein Unternehmen für medizinische Geräte in der kommerziellen Phase, das sich auf anpassbare, schnittfreie Therapien spezialisiert hat, wird am Dienstag, den 19. November 2024, um 9:45 Uhr Eastern Time in New York ein Update auf der Stifel 2024 Healthcare Conference vorstellen.
Die Präsentation wird live und archiviert auf der Website des Unternehmens im Bereich 'Webcasts' im Investorenbereich verfügbar sein.
- None.
- None.
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 9:45 a.m. Eastern Time in NYC.
The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for pixel-by-pixel precision to preserve prostate disease patients’ urinary continence and sexual function, while killing the targeted prostate tissue via a precise sound absorption technology that gently heats it to kill temperature (55-57°C). TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When is Profound Medical presenting at the Stifel 2024 Healthcare Conference?
Where can I watch the Profound Medical presentation at the Stifel 2024 Healthcare Conference?
What is the stock symbol for Profound Medical?
What type of therapies does Profound Medical develop?
